Astragalosides promote angiogenesis via vascular endothelial growth factor and basic fibroblast growth factor in a rat model of myocardial infarction

Molecular Medicine Reports

Volumn 12, Issue 5, 2015, Pages 6718-6726

  Yu, Jun Min ^a   Zhang, Xiao Bo ^a   Jiang, Wen ^a   Wang, Hui Dong ^a   Zhang, Yi Na ^a  

^a HARBIN MEDICAL UNIVERSITY   (China)

Author keywords

Angiogenesis; Astragaloside; Basic fibroblast growth factor; Myocardial infarction; Vascular endothelial growth factor

Indexed keywords

ANGIOGENESIS MODULATOR; ASTRAGALOSIDE; BASIC FIBROBLAST GROWTH FACTOR RECEPTOR; BLOOD CLOTTING FACTOR 8; FIBROBLAST GROWTH FACTOR 2; MESSENGER RNA; SAPONIN; UNCLASSIFIED DRUG; VASCULOTROPIN; ANGIOGENIC FACTOR; ASTRAGALOSIDE A; TRITERPENE; VASCULAR ENDOTHELIAL GROWTH FACTOR A, RAT; VASCULOTROPIN A;

ADULT; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIANGIOGENIC ACTIVITY; ARTICLE; CAPILLARY DENSITY; CELL COUNT; CELL INFILTRATION; CONTROLLED STUDY; DRUG EFFECT; DRUG MEGADOSE; FIBROBLAST; HEART FAILURE; HEART INFARCTION; HEART INFARCTION SIZE; HEART LEFT VENTRICLE MASS; HEART MUSCLE; LOW DRUG DOSE; MALE; MUSCLE HYPERTROPHY; NONHUMAN; PROTEIN BLOOD LEVEL; PROTEIN EXPRESSION; RAT; UPREGULATION; ANGIOGENESIS; ANIMAL; CARDIAC MUSCLE; CORONARY BLOOD VESSEL; DISEASE MODEL; DRUG EFFECTS; GENE EXPRESSION; MICROVASCULATURE; MYOCARDIAL INFARCTION; PATHOLOGY; PATHOPHYSIOLOGY; PHYSIOLOGY; PRECLINICAL STUDY; WISTAR RAT;

ANGIOGENESIS INDUCING AGENTS; ANIMALS; CORONARY VESSELS; DISEASE MODELS, ANIMAL; DRUG EVALUATION, PRECLINICAL; FIBROBLAST GROWTH FACTOR 2; GENE EXPRESSION; MALE; MICROVESSELS; MYOCARDIAL INFARCTION; MYOCARDIUM; NEOVASCULARIZATION, PHYSIOLOGIC; RATS, WISTAR; SAPONINS; TRITERPENES; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 84943624375     PISSN: 17912997     EISSN: 17913004     Source Type: Journal    
DOI: 10.3892/mmr.2015.4307     Document Type: Article

References (38)

1. Orphanou K, Stassopoulou A and Keravnou E: Risk assessment for primary coronary heart disease event using dynamic Bayesian networks. In: Artificial Intelligence in Medicine. Holmes J, Bellazzi R, Sacchi L and Peek N (eds). Vol 9105. Springer International Publishing, pp161-165, 2015.
2. Liu Y and Liu RX: The research progress of Traditional Chinese medicine in treatment of coronary atherosclerosis heart disease. Hebei J of Trad Chin Med 35: 1476-1478, 2013 (In Chinese).
3. Tao HM, Qin S and Zhang DY: Research progress of coronary heart disease in women. Adv Cardiovasc Dis 35: 250-253, 2014 (In Chinese).
4. Go AS, Mozaffarian D, Roger VL, Benjamin EJ, Berry JD, Borden WB, Bravata DM, Dai S, Ford ES, Fox CS, et al: Executive summary: Heart disease and stroke statistics-2013 update: A report from the American heart association. Circulation 127: 143-152, 2013.
5. Li XY and Fu ZQ: Pharmacotherapy of coronary heart disease in the elderly. J Med Res 40: 3-5, 2011 (In Chinese).
6. de bakker JM, van capelle FJ, Janse MJ, Wilde AA, Coronel R, Becker AE, Dingemans KP, van Hemel NM and Hauer RN: Reentry as a cause of ventricular tachycardia in patients with chronic ischemic heart disease: Electrophysiologic and anatomic correlation. Circulation 77: 589-606, 1988.
7. Wang LM, Zhang SD and Ann YC: Treatment of ventricular arrhythmia after myocardial infarction. Chinese Journal of Cardiovascular Review 6: 144-146, 2008 (In Chinese).
8. Meng QC: Treatment and prevention of reperfusion arrhythmia after thrombolytic therapy for acute myocardial infarction. Journal of Medical Forum 27: 55-57, 2006 (In Chinese).
9. Bates ER and Topol EJ: Limitations of thrombolytic therapy for acute myocardial infarction complicated by congestive heart failure and cardiogenic shock. J Am Coll Cardiol 18: 1077-1084, 1991.
10. Kones R: Primary prevention of coronary heart disease: Integration of new data, evolving views, revised goals and role of rosuvastatin in management. A comprehensive survey. Drug Des Devel Ther 5: 325-380, 2011.
11. Ware JA and Simons M: Angiogenesis in ischemicheart disease. Nat Med 3: 158-164, 1997.
12. Rissanen TT, Korpisalo P, Markkanen JE, Liimatainen T, Orden MR, Kholova I, de Goede A, Heikura T, Grohn OH and Yla-Herttuala S: Blood flow remodels growing vasculature during vascular endothelial growth factor gene therapy and determines between capillary arterialization and sprouting angiogenesis. Circulation 112: 3937-3946, 2005.
13. Dragneva G, Korpisalo P and Yla-Herttuala S: Promoting blood vessel growth in ischemic diseases: Challenges in translating preclinical potential into clinical success. Dis Model Mech 6: 312-322, 2013.
14. Liu Q, Li J, Wang J, Li J, Janicki JS and Fan D: Effects and mechanisms of Chinese herbal medicine in ameliorating myocardial ischemia-reperfusion injury. Evid Based Complement Alternat Med 2013: 925625, 2013.
15. Liu YF, Liu SW and Liu ZX: Effects of Ginsenosiee Rb1 on blood vessel regeneration after ischemia and reperfusion in rats. Chin J Histochem Cytochem 17: 39-44, 2008 (In Chinese).
16. Han D, Zhang Y, Liu M, et al: The hemodynamic and antioxidant effects of Astragaloside on ventricular remodeling rats. Chin J Lab Diag 17: 1956-1959, 2013 (In Chinese).
17. Wang YP, Li XY, Song CQ and Hu ZB: Effect of astragaloside IV on T, B lymphocyte proliferation and peritoneal macrophage function in mice. Acta Pharmacol Sin 23: 263-266, 2002.
18. Yin Y, Li WP, Gong HL, Zhu FF, Li WZ and Wu GC: Protective effect of astragaloside on focal cerebral ischemia/reperfusion injury in rats. Am J Chin Med 38: 517-527, 2010.
19. Yang JS, Yu JM, Ju L, et al: Effects of Astragalosides on angiogenesis in myocardium infarction rats. Chin J Prim Med Pharm 19: 215-217, 2012.
20. Zhang L, Liu Q, Lu L, Zhao X, Gao X and Wang Y: Astragaloside IV stimulates angiogenesis and increases hypoxia-inducible factor-1 accumulation via phosphatidylinositol 3-kinase/Akt pathway. J Pharmacol Exp Ther 338: 485-491, 2011.
21. De Luca A, Carotenuto A, Rachiglio A, Gallo M, Maiello MR, Aldinucci D, Pinto A and Normanno N: The role of the EGFR signaling in tumor microenvironment. J Cell Physiol 214: 559-567, 2008.
22. Bottcher RT and Niehrs C: Fibroblast growth factor signaling during early vertebrate development. Endocr Rev 26: 63-77, 2005.
23. Andersson H and Brittebo E: Proangiogenic effects of environmentally relevant levels of bisphenol A in human primary endothelial cells. Arch Toxicol 86: 465-474, 2012.
24. Clark JD, Gebhart GF, Gonder JC, Keeling ME and Kohn DF: Special Report: The 1996 Guide for the Care and Use of Laboratory Animals. ILAR J 38: 41-48, 1997.
25. Reddy BY, Greco SJ, Patel PS, Trzaska KA and Rameshwar P: RE-1-silencing transcription factor shows tumor-suppressor functions and negatively regulates the oncogenic TAC1 in breast cancer cells. Proc Natl Acad Sci U S A 106: 4408-4413, 2009.
26. Weidner N: Intratumor microvessel density as a prognostic factor in cancer. Am J Pathol 147: 9-19, 1995.
27. Aurgemma GP and Gaasch WH: Quantitative evaluation of left ventricular structure, wall stress, and systolic function. In: The Practice of Clinical Echocardiography. Otto CM (ed). 2nd edition. Elsevier Saunders, Philadelphia, PA, pp65-87, 2002.
28. Meiners S, Dreger H, Fechner M, Bieler S, Rother W, Gunther C, Baumann G, Stangl V and Stangl K: Suppression of cardiomyocyte hypertrophy by inhibition of the ubiquitin-proteasome system. Hypertension 51: 302-308, 2008.
29. Cochain C, Channon KM and Silvestre JS: Angiogenesis in the infarcted myocardium. Antioxid Redox Signal 18: 1100-1113, 2013.
30. Hicklin DJ and Ellis LM: Role of the vascular endothelial growth factor pathway in tumor growth and angiogenesis. J Clin Oncol 23: 1011-1027, 2005.
31. Pohl-Schickinger A, Koehne P, Schmitz T, Schmitt KR, Hubler M, Redlin M, Berger F and Stiller B: Vascular endothelial growth factor and its soluble receptor in infants with congenital cardiac disease. Cardiol Young 20: 505-508, 2010.
32. Shibuya M: VEGF-VEGFR signals in health and disease. Biomol Ther 22: 1-9, 2014.
33. Wafai R, Tudor EM, Angus JA and Wright CE: Vascular effects of FGF-2and VEGF-B in rabbits with bilateral hind limb ischemia. J Vasc Res 46: 45-54, 2009.
34. Schirmer SH, van Nooijen FC, Piek JJ and van Royen N: Stimulation of collateral artery growth: Travelling further down the road to clinical application. Heart 95: 191-197, 2009.
35. Zhang Y, Hu G, Li S, Li ZH, Lam CO, Hong SJ, Kwan YW, Chan SW, Leung GP and Lee SM: Pro-angiogenic activity of astragaloside IV in HUVECs in vitro and zebrafish in vivo. Mol Med Rep 5: 805-811, 2012.
36. Karanu FN, Murdoch B, Gallacher L,Wu DM, Koremoto M, Sakano S and Bhatia M: The notch ligand jagged-1 represents a novel growth factor of human hematopoietic stem cells. J Exp Med 192: 1365-1372, 2000.
37. Benedito R, Roca C, Sörensen I, Adams S, Gossler A, Fruttiger M and Adams RH: The notch ligands Dll4 and Jagged1 have opposing effects on angiogenesis. Cell 137: 1124-1135, 2009.
38. Hernandez SL, Banerjee D, Garcia A, Kangsamaksin T, Cheng WY, Anastassiou D, Funahashi Y, Kadenhe-Chiweshe A, Shawber CJ, Kitajewski JK, et al: Notch and VEGF pathways play distinct but complementary roles in tumor angiogenesis. Vasc Cell 5: 17, 2013.